Rimouski (Quebec), February 7, 2018 – innoVactiv, a Canadian company dedicated to the development of science-based specialty ingredients, announces today that its latest human clinical study supporting the efficacy of InSea2® to beneficially affect post-meal cognition and mental energy has been accepted for publication in the January issue of the peer-reviewed journal Nutrients.

Under normal circumstances, post-meal fluctuations in blood glucose and insulin induce what is commonly felt as food coma. Based on its beneficial impact on post-meal blood glucose, it was hypothesized that InSea2® could help sustain brain function in this critical post-meal period. Recently, a human clinical trial conducted by the Brain, Performance and Nutrition Research Center of Northumbria University (UK) showed that InSea2® can help alleviate symptoms of food coma.

“We are really excited about these new results being published, as they open a new market segment for InSea2® as a caffeine-free support for cognition. Many persons feel the sudden urge to nap after eating or have other kinds of cognitive effects such as a decline in concentration. Using InSea2® before meal can support optimal cognition by promoting a healthier, more gradual absorption of dietary carbs and for avoiding large insulin release”, explains Jocelyn Bérubé, Executive Vice-President, Scientific and Regulatory Affairs at innoVactiv.

February 2nd, 2018 (Kensington, PE Canada) – Natures Crops International and Stratum Nutrition (Carthage, MO) have entered into a value-added distribution agreement covering the dietary supplement marketplace in North America. This alliance adds strategic value for both companies through each company’s leading dietary products addressing wellness needs in joint and digestive health. Both companies have achieved clinically-proven, peer-reviewed scientific evidence with resulting publications supporting a healthy inflammatory response.

Andrew Hebard, Founder and CEO of Natures Crops International stated, “In the management team at Stratum led by Micah Osborne, we have aligned with a high-integrity company who have proven their ability to stimulate demand and commercialize strong science-backed proprietary ingredients. Ahiflower oil continues to proliferate rapidly in dietary supplements in North America, so we truly appreciate the added sales and customer support that Stratum brings to the forefront, while we develop novel product formulations utilizing each company’s proprietary ingredients.” Both companies see excellent synergies resulting from this supply and distribution partnership.

Micah Osborne, President and 3rd generation family owner of Stratum Nutrition said, “Stratum is well on a path to leadership in supplying all-natural and proven-effective dietary solutions. Bringing plant-based Ahiflower into Stratum’s highly selective portfolio fully complements the range of unique plant, animal, and probiotic ingredients we produce and distribute. We are also very excited to bring Ahiflower into our ongoing clinical trial models.” A strength of both
companies is their insistence on robust, peer-reviewed clinical science backing their vertically integrated ingredient supply systems.

Stratum Nutrition will initially represent Ahiflower oil supply to new clients in human dietary supplement markets in North America (USA, Canada, Mexico). Existing end user brands that have been supplied by Natures Crops will continue to be supported directly by Natures Crops. Ahiflower oil is manufactured exclusively by Natures Crops and licensed to over 25 brands in the EU and North America. Ahiflower oil launched into equine supplement markets in the UK,
USA, and Canada in 2017.

An interesting recent review of S-Adenosyl-methionine (SAMe), published at the end of 2017, has provided a broad perspective on the role, efficacy and safety of SAMe in the treatment of depression, neuropsychiatric disorders, and co-morbid medical conditions.

The remarkable work of Sharma et al. has taken into consideration 132 studies – 115 clinical and 17 preclinical studies – and has provided evidence that oral doses of SAMe between 200mg and 3200 mg have similar efficacy to Tricyclic Antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) and are superior to placebo in ameliorating depressive symptoms and Depression and Quality of Life rating scales.

SAMe may also be effective in combination with other antidepressants, both TCAs (Tricyclic antidepressants) and SSRIs (Selective Serotonin Reuptake Inhibitors), in case of inadequate response to drug therapy and patients with depression associated to other medical conditions i.e. HIV, Parkinson’s disease, osteoarthritis and fibromyalgia. In these two latter diseases, SAMe exerts anti-inflammatory and analgesic activity by enhancing proteoglycan bioactivity.

Furthermore, SAMe antidepressant activity has been associated with a greater speed of onset in comparison with TCAs which can take up to two weeks to improve symptoms. This supplement can be also successfully used in addition to standard antipsychotic drugs in order to improve quality of life and reduce aggressive behaviour in a subset of schizophrenic patients with low-active Catechol-O-Methyltransferase (COMT) activity. The authors conclude that SAMe supplementation holds promise for several neuropsychiatric conditions (Sharma 2017 https://www.ncbi.nlm.nih.gov/pubmed/28682528). Similar results were found by a Cochrane review in 2016 published by Galizia et al.

The highlights reported on SAMe may represent a promising alternative to the treatment of depression, neuropsychiatric disorders, and co-morbid medical conditions. In fact, the risks of SAMe compare quite favorably with prescription antidepressants, particularly in that it does not cause sexual dysfunction or weight gain (two of the most common causes for antidepressant discontinuation) and it is less likely to be life-threatening in patients who are at risk for overdosing during suicide attempts. Knowing that evidence generally supports the safety and efficacy of SAMe in both psychiatric and medical illnesses could impact clinical decision making.

As a Complementary, Alternative, and Integrative Medicine (CAIM) therapy, SAMe has been utilized for treatment of psychiatric and medical conditions in Europe for over 30 years. In the United States, it became better known after 1999 as an over-the-counter dietary supplement under the Dietary Supplement Health and Education Act (DSHEA).

Silvia Pisoni, Marketing Manager of Gnosis, the Italian-based biotechnology company leader in the manufacturing of both pharmaceutical and nutraceutical grade of SAMe, commented: “SAMe has been discovered as early as in 1952 by Italian scientist Giulio Cantoni, and after decades of use in several countries it still moves the interest of researchers and scientists. The exploration of the full range of potential benefits of SAMe through controlled clinical studies needs to go ahead considering the broad range of reactions where this human biochemical methyl donor is involved – including multiple crucial biochemical pathways, such as the biosynthesis of hormones and neurotransmitters – and the new aspects that are recently emerging”.

She continued: “Abnormal levels of SAMe in the body have been reported in several disease states, and SAMe applications in human health are still underestimated. SAMe is the most active methyl donor produced in the human body and it is essential to sustain the normal function of the one carbon metabolism pathway. It has role in the methylation of DNA and may take part in the control of stress stimuli and in the mechanisms of ageing physiology and physiopathology, providing a natural help to sustain biological functions, integrate possible nutritional deficiencies caused by the modern way of life, ensure an healthy ageing, support the body and mental wellness.”

Gnosis has over 30 years of experience in SAMe production from a selected highly productive yeast using fermentation technologies and boasts more than 10 patents about proprietary stabilization of salts and the production of innovative forms of oral dosage covered by several granted patents and patent pending applications. SAMe produced by Gnosis is commercialized under the brand name of Adonat^®.

1. Sharma A, Gerbarg P, Bottiglieri T, Massoumi L, Carpenter LL, Lavretsky H, Muskin PR, Brown RP, Mischoulon D; as Work Group of the American Psychiatric Association Council on Research. S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research. J Clin Psychiatry. 2017
2. Galizia I, Oldani L, Macritchie K, Amari E, Dougall D, Jones TN, Lam RW, Massei GJ, Yatham LN, Young AH. S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database Syst Rev. 2016
3. William JW. Nutrient Power: Heal Your Biochemistry and Heal Your Brain Skyhorse Publishing Inc 2012.
4. Choi SW et al. Epigenetics: a new bridge between nutrition and health. Advances in Nutrition: An International Review Journal, 2010

This year LEHVOSS Iberia and Gee Lawson will be exhibiting at Nutraceuticals Europe. Come to the Feria de Madrid on the 14th or 15th of February, stop by the LEHVOSS Iberia stand E40  and learn about the Gee Lawson range of ingredients and solutions.

Take the opportunity to learn about EpiCor’s unique attributes and scientific research by listening to Dr. Justin Green, PhD Director of Scientific Affairs at Embria Health Sciences,  at his presentation on Thursday 15th of February 11am, in the Seminar Theater.

A winning research of the year (Nutraingredients Awards, 2015) indicated that, just one hour after treatment with a single 400mg dose of Longvida®, healthy older participants showed superior performance over placebo on validated tasks relating to attention and working memory. In addition, a 30-day supplementation improved measures of calmness, contentedness and fatigue versus placebo.

The study included 60 participants, and no dropouts or side effects were reported. Furthermore, the authors suggested a possible mechanism by which the effects of Longvida® to support energy were observed in less than one hour.

Longvida® contains the natural antioxidant curcumin, optimized by SLCP™ technology for maximum bioavailability into blood and target tissues. It supplies significant levels of free (not glucuronidated or inactivated) curcumin, and this has led to clinically and statistically significant results in clinical trials.

Few supplement ingredients can boast about 100,000+ published studies. Glutathione has carved an enviable niche in the supplement sector. And the evidence keeps growing, showcasing dramatic new applications and proven results for this antioxidant powerhouse.

Join us as we uncover new horizons and marketing opportunities for glutathione including skin brightening, sports nutrition and liver/GI health support.

Think you know everything about glutathione? Think again. Join our panel of experts to learn more and see the future.

Click here for registration.

Start Date:21 February 2018

Start Time:10am EST (NY)/ 3pm GMT (London)

Duration:60 minutes

Curcuma longa has been well documented for managing joint inflammation and pain. The present study investigated the effect of polar extract of C. longa (NR-INF-02) on cartilage homeostasis in human articular chondrocytes knee (NHAC-kn) cells to understand its plausible mechanism of action.
*NR-INF-02 ( Turmacin)

Salient features of the study:

1.The main feature of osteoarthritis (OA) is damage to the tissue known as articular cartilage.

2. Ageing, trauma, mechanical stress, metabolic syndrome causes rupture of cartilage homeostasis via promoting synthesis of cartilage damaging factors.

3. Turmacin (NR-INF-02) has been investigated for its effects on restoring cartilage homeostasis via inhibiting cartilage damaging factors.

4. Turmacin (NR-INF-02) inhibited cartilage damaging pathways/factors such as NF-kB, IL-1beta, IL-6, IL-8, TNF-alfa, ICAM-1, COX-2 and PGF2 and protected glycosaminoglycans and collagen, which are the structural components of cartilage.

Methods
Dysregulation of cartilage homeostasis was induced by IL-1β and H2O2. Modulating effects of NR-INF-02 on degradation markers viz., chondrocyte apoptosis, senescence, cytokine, eicosanoids, and cartilage synthesis markers viz., glycosaminoglycans and type II collagen degradation was evaluated in human articular chondrocytes knee (NHAC-kn) cells. Further, the effect of NR-INF-02 on lipopolysaccharide (LPS)-induced expression of NF-kB in RAW264.7 macrophages was investigated.

Results
NR-INF-02 significantly attenuated IL-1β-induced chondrocyte cytotoxicity, apoptosis and release of chondrocyte degradation markers such as IL-6, IL-8, COX-2, PGE2, TNF-α, ICAM-1 in NHAC-kn cells. Also, NR-INF-02 protected IL-1β-induced damage to synthesis markers such as glycosaminoglycans, type II collagen and further attenuated H2O2-induced chondrocyte senescence. In addition NR-INF-02 suppressed LPS-induced NF-kB expression in RAW264.7 cells.
Conclusions
NR-INF-02 protects cartilage homeostasis by maintaining the balance between synthesis and degradation of cartilage matrix.

Publication: Inflammopharmacology Experimental and Therapeutic Studies ( Springer )To view full text , please refer : http://rdcu.be/ElZ8

DES MOINES, Iowa (December 21, 2017) – Kemin was recently granted an additional patent that supports the technology behind its patented lines of spearmint, KI110 and KI42. The patented spearmint lines are used to develop Kemin’s cognition-enhancing ingredient, Neumentix™ Phenolic Complex K110-42. The newest patent covers the unique drying process used to retain health-benefitting polyphenols from the harvested spearmint.

Naturally occurring polyphenols in KI110 and KI42 spearmint lines include rosmarinic, salvianolic and caftaric acids. Research shows these polyphenols may act as antioxidants to reduce oxidative stress, promote new neuron growth and protect nerve cells in the brain.¹

Spearmint is a seasonal herb that retains high levels of moisture. To preserve perishable polyphenols in spearmint, post-harvest drying is required. However, aromatic herbs are especially sensitive to post-harvest processing, resulting in discoloration and decreased nutritional value. Kemin’s patented drying process successfully minimizes moisture while preserving the nutritional value of the spearmint.

“Removing most of the water from the plant material without destroying the rosmarinic acid allows us to extract dried material when there’s demand, so that customers receive product at the height of its nutritional value,” said Dr. John Greaves, VP of Specialty Crops at Kemin Industries.

Once dried, polyphenols from Kemin’s KI110 and KI42 spearmint lines are water extracted to produce Neumentix, which can be formulated into a variety of supplement or food applications.

Natural Remedies continues to add recognitions by receiving upcoming research based Phytoceuticals company in Nutrition and wellness Awards 2017 hosted by CIMS Medica.

Nutrition and wellness Awards recognizes the excellence in nutraceutical industry under various domains including research & development, manufacturing, packaging, distribution and other support services in the areas of active ingredients, procedures, practices, technologies, and finished products.
Natural Remedies, a leading research-based company is in the forefront of phytopharmaceutical innovations.  Our ground-breaking approach of integrating traditional knowledge with modern science makes our Research & Development capability stand class apart in the industry. Our R&D team strives for constant innovations to deliver breakthrough & best quality products

This recognition has further motivated us to build on our R&D capability & inspires us to create many more innovations  for future

On November 24^th, the Minister for Medical Care (The Netherlands) sent an Official Notice to Gnosis with the approval for the placing of Chondroitin Sulfate (Mythocondro^®) on the market in the EU pursuant to Regulation (EC) No. 258/97 Article 4.2 first indent.

Gnosis SpA in Desio, Italy, may market Mythocondro^®, the Non-Animal Chondroitin Sulfate (CS) of fermentation origin, in the European Union as a Novel Food Ingredient to be used in food supplements as defined in Directive 2002/46 / EC on the approximation of the laws of the Member States relating to food supplements. This opens the door to the commercialization of Mythocondro^® from Gnosis, in the overall EU.

This key milestone is part of the global strategic plan of Gnosis that started in the USA with the granted GRAS Status of Mythocondro^® and the commercialization of the first products with the novel ingredient, in 2017.

With this act, the entire process of registration of Mythocondro^® in EU is closed and, starting from the beginning of 2018, the first supplements with the only vegetarian and vegan Chondroitin Sulfate will get finally the EU market.

“This achievement represents an important step forward for our company that has strenuously believed in this project since its beginnings. Even more Mythocondro® represents a huge and long waited step forward for the entire global chondroitin market, always hovering between the clinical value of this is active ingredient – widely established by a large number of human trials with quality-controlled CS – and the serious concerns about the quality of the raw materials commercialized.” – said Marco Berna, Business Development Director of Gnosis.

He said again: “Today, within the nutraceuticals industry, CS is acknowledged as one of the most adulterated supplements in the market. Mythocondro® promises to change entirely the CS market, because it is the first Non-Animal Chondroitin Sulfate obtained through a fermentation-based manufacturing process, developed and patented by using a pharmaceutical approach, ensuring strict quality standards and providing a reliable and reproducible source of CS, able to definitely solve concerns related to poor quality of animal derived CS.”